MBXMBX Biosciences, Inc.

Healthcare
$53.26+433% 1Y

Price

+433%1Y

End-of-day closes, not the intraday tick.

The five questions

2 of 5 available

Only two of the five can be answered for MBX today. The rest need figures this filer has not published. The tabs above still show whatever data does exist.

  • Is the business good?not enough filed
  • Is it safe?Watch
  • Is the price fair?not enough filed
  • Is it growing?not enough filed
  • What is the market doing?Mixed
What they do

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™ ("PEP™") platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

In the company’s own words · 10-K filed Mar 12, 2026 · SEC EDGAR

P/En/a
Market value$2.40B
1 year+433%
5 yearsn/a

Charts

As reported to the SEC, without any scoring.

The next results filing is expected around Nov 5, 2026, the same week as a year ago.

What the company said

The company's own words from its current reports to the SEC, newest first

  1. Aug 27, 2026On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP)Regulation FD disclosure · Form 8-K
  2. Aug 6, 2026On August 6, 2026, the Company provided an update on its MBX 4291 phase 1 clinical trial. The Company remains on track to report data from the first cohort of the 12-week multiple ascending dose (Part C) in the fourth quarter of 2026.Earnings release · Form 8-K
  3. Jul 13, 2026Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.

Biotechnology

The closest names by size in the same industry

Compare peers
SLBT-1.3%
SL Science Holding Limited
PHVS+0.05%
Pharvaris N.V.
NRIX+0.68%
Nurix Therapeutics, Inc.
MLYS+4.4%
Mineralys Therapeutics, Inc.
BHVN+1.3%
Biohaven Ltd.
MRVI+3.7%
Maravai LifeSciences Holdings, Inc.